CORONA REMEDIES LIMITED FILES DRHP WITH SEBI TO RAISE UPTO ₹ 800 CRORE THROUGH IPO
ChrysCapital affiliate, Sepia Investments-backed Corona Remedies Limited, anIndia focused branded pharmaceutical formulation company has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).
The company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas and it plans to raise funds through initial public offerings (IPO) aggregating up to ₹800 Crore. The entire ₹800 Crore is an Offer For Sale.
The Equity Shares are proposed to be listed on the BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”).
JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) & Kotak Mahindra Capital Company Limitedare the Book Running Lead Managers to the issue.